Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
暂无分享,去创建一个
P. Emery | J. Baker | P. Conaghan | Subhashish Banerjee | M. Østergaard | H. Ahmad | Y. Elbez | T. Huizinga
[1] H. Bliddal,et al. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. , 2020, Rheumatology.
[2] A. H. M. van der Helm-van Mil,et al. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability , 2020, RMD Open.
[3] P. Maffia,et al. Molecular imaging of inflammation - Current and emerging technologies for diagnosis and treatment. , 2020, Pharmacology & therapeutics.
[4] J. Baker,et al. Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis , 2020, Arthritis care & research.
[5] J. Smolen,et al. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. , 2019, Rheumatology.
[6] D. Furst,et al. Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study , 2019, RMD Open.
[7] L. Terslev,et al. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors , 2018, Rheumatology.
[8] A. Barton,et al. Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.
[9] Publisher's Note , 2018, Anaesthesia.
[10] P. Emery,et al. Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis , 2017, Annals of the rheumatic diseases.
[11] E. Sasso,et al. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes , 2017, Rheumatology.
[12] P. Emery,et al. Development and validation of rheumatoid arthritis magnetic resonance imaging inflammation thresholds associated with lack of damage progression. , 2017, Clinical and experimental rheumatology.
[13] R. Landewé,et al. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis , 2017, RMD Open.
[14] M. Dougados,et al. 2016 update of the EULAR recommendations for the management of early arthritis , 2016, Annals of the rheumatic diseases.
[15] P. Emery,et al. Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis , 2016, Annals of the rheumatic diseases.
[16] P. Conaghan,et al. FRI0513 Validating Mri-Detected Inflammation Thresholds Predictive of Structural Damage Progression in Patients with Rheumatoid Arthritis in A Randomized Placebo-Controlled Trial , 2016 .
[17] J. Smolen. Treat-to-target as an approach in inflammatory arthritis , 2016, Current opinion in rheumatology.
[18] L. March,et al. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set , 2016, RMD Open.
[19] G. Ferraccioli,et al. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission , 2016, Arthritis Research & Therapy.
[20] Raveendhara R. Bannuru,et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis care & research.
[21] W. Robinson,et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial , 2015, Annals of the rheumatic diseases.
[22] E. Naredo,et al. Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. , 2015, Rheumatology.
[23] M. Dougados,et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.
[24] D. Furst,et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period , 2014, Annals of the rheumatic diseases.
[25] T. Iwamoto,et al. Prediction of Relapse After Discontinuation of Biologic Agents by Ultrasonographic Assessment in Patients With Rheumatoid Arthritis in Clinical Remission: High Predictive Values of Total Gray‐Scale and Power Doppler Scores That Represent Residual Synovial Inflammation Before Discontinuation , 2014, Arthritis care & research.
[26] Andrew K. Brown,et al. Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity , 2014, The Journal of Rheumatology.
[27] P. Emery,et al. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial , 2013, Annals of the rheumatic diseases.
[28] P. Conaghan,et al. Imaging tools in rheumatoid arthritis: ultrasound vs magnetic resonance imaging. , 2012, Rheumatology.
[29] Mahboob Rahman,et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial , 2011, Annals of the rheumatic diseases.
[30] David T Felson,et al. UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .
[31] B. Dijkmans,et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study , 2010, Annals of the rheumatic diseases.
[32] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[33] Tsutomu Takeuchi,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.
[34] John Wong,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.
[35] P. Emery,et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? , 2010, Annals of the rheumatic diseases.
[36] C. Peterfy,et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. , 2008, Arthritis and rheumatism.
[37] C. Peterfy,et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. , 2006, Arthritis and rheumatism.
[38] P. V. van Riel,et al. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. , 2004, Rheumatology.
[39] Paul Bird,et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. , 2003, The Journal of rheumatology.
[40] Raveendhara R. Bannuru,et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .